CC Chemokine Receptor 5 ?32 and CC Chemokine Receptor 2 64I Polymorphisms Do Not Influence the Virologic and Immunologic Response to Antiretroviral Combination Therapy in Human Immunodeficiency Virus Type 1–Infected Patients
- 15 December 2002
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (12) , 1726-1732
- https://doi.org/10.1086/345677
Abstract
To investigate the influence of the CC chemokine receptor 2 64I and CC chemokine receptor 5 Δ32 polymorphisms on the virologic and immunologic response of human immunodeficiency virus type 1 (HIV-1)–infected patients to highly active antiretroviral therapy, data from 4 clinical studies were pooled. The prevalence of the CCR5 Δ32 polymorphism was 21% (27 of 130 subjects), and the prevalence of the CCR2 64I polymorphism was 15% (19 of 130 subjects). There were no major differences between subjects with and without polymorphisms in the CCR5 and/or CCR2 genes with respect to the rate of initial viral clearance, proportion of subjects with plasma HIV-1 RNA levels below the lower limit of quantification, rate of virologic treatment failure, immunologic responses, and disease progression during 96 weeks of follow-upKeywords
This publication has 0 references indexed in Scilit: